CLASS ACTION UPDATE for MGNX, VRAY, MTCH and CVET: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

  • October 23, 2019
  • Home
  • USA
  • CLASS ACTION UPDATE for MGNX, VRAY, MTCH and CVET: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, Oct. 23, 2019 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.MacroGenics, Inc. (NASDAQGS: MGNX)
Class Period:
February 6, 2019 – June 3, 2019
Lead Plaintiff Deadline: November 12, 2019
Join the action: https://www.zlk.com/pslra-1/macrogenics-inc-loss-form?wire=3
Allegations: MacroGenics, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (a) the Company had conducted the progression-free survival (“PFS”) and first interim overall survival (“OS”) analyses for the SOPHIA trial by no later than October 10, 2018; (b) the October 2018 PFS analysis showed a 0.9 month improvement in PFS; and (c) the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves crossed in several spots (thereby violating the constant hazard assumption) and separated late.To learn more about the MacroGenics, Inc. class action contact [email protected].
ViewRay, Inc. (NASDAQ: VRAY)
Class Period:
March 15, 2019 – August 8, 2019
Lead Plaintiff Deadline: November 12, 2019
Join the action: https://www.zlk.com/pslra-1/viewray-inc-loss-form?wire=3
Allegations: ViewRay, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) demand for ViewRay systems had declined due in part to changes being made to Medicare reimbursement approaches first announced in November 2019 that could make purchases of new ViewRay systems less profitable for customers; (b)  the Company’s reported backlog was overstated due to the inclusion of orders with insufficient surety as to permit for their inclusion in reported backlog; and (c) as a result of the foregoing, defendants’ positive statements about ViewRay’s business metrics and financial prospects during the Class Period were materially false and misleading and/or lacked a reasonable basis.To learn more about the ViewRay, Inc. class action contact [email protected].
Match Group, Inc. (NASDAQ: MTCH)
Class Period:
August 6, 2019 – September 25, 2019
Lead Plaintiff Deadline: December 2, 2019
Join the action: https://www.zlk.com/pslra-1/match-group-inc-loss-form?wire=3
Allegations: During the class period, Match Group, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company used fake love interest ads to convince customers to buy and upgrade subscriptions; (2) the Company made it difficult and confusing for consumers to cancel their subscriptions; (3) as a result, the Company was reasonably likely to be subject to regulatory scrutiny; (4) the Company lacked adequate disclosure controls and procedures; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.To learn more about the Match Group, Inc. class action contact [email protected].
Covetrus, Inc. (NASDAQ: CVET)
Class Period:
February 8, 2019 – August 12, 2019
Lead Plaintiff Deadline: November 29, 2019
Join the action: https://www.zlk.com/pslra-1/covetrus-inc-loss-form?wire=3
Allegations: Covetrus, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company had overstated its capabilities with regard to inventory management and supply chain services; (ii) Covetrus had understated the costs of the integration of Henry Schein’s Animal Health Business and VFC, including the timing and nature of those costs; (iii) Covetrus had understated its separation costs from Henry Schein; and (iv) the Company understated the impact on earnings from online competition and alternative distribution channels as well as the impact of the loss of a large customer in North America just prior to the Company’s separation from Henry Schein.To learn more about the Covetrus, Inc. class action contact [email protected].
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow